1879071-89-2

1879071-89-2 structure
1879071-89-2 structure
  • Name: EGFR/HER2-IN-4
  • Chemical Name: EGFR/HER2-IN-4
  • CAS Number: 1879071-89-2
  • Molecular Formula: C24H27ClFN5O3
  • Molecular Weight: 487.95
  • Catalog: Signaling Pathways JAK/STAT Signaling EGFR
  • Create Date: 2022-09-03 02:59:31
  • Modify Date: 2024-01-27 07:03:47
  • EGFR/HER2-IN-4(compound 6d) is an orally active irreversible dual inhibitor. EGFR/HER2-IN-4 inhibits EGFR with an IC50 value of 0.6 nM and demonstrates potent EGFR kinase inhibitory activities on L858R and T790M mutations. EGFR/HER2-IN-4 has potent antitumor efficacy in vivo and can be used for lung cancer research[1].

Name EGFR/HER2-IN-4
Description EGFR/HER2-IN-4(compound 6d) is an orally active irreversible dual inhibitor. EGFR/HER2-IN-4 inhibits EGFR with an IC50 value of 0.6 nM and demonstrates potent EGFR kinase inhibitory activities on L858R and T790M mutations. EGFR/HER2-IN-4 has potent antitumor efficacy in vivo and can be used for lung cancer research[1].
Related Catalog
Target

EGFR:0.6 nM (IC50)

HER2

In Vitro EGFR/HER2-IN-4 (compound 6d) (0-10 μM, 72 hours) shows well anti-proliferative activity against human non-small cell lung cancer cell lines NCI-H1975 (T790M), HCC 827 (L858R) and human epithelial carcinoma cell lines A431[1]. Cell Proliferation Assay[1] Cell Line: Human non-small cell lung cancer cell lines NCI-H1975 (T790M), HCC 827 (L858R), Human epithelial carcinoma cell lines A431 Concentration: 0-10 μM Incubation Time: 72 hours Result: Inhibited NCI-H1975 cells, HCC 827 cells, A431 cells with the IC50values of 107 nM,0.2 nM and 20 nM respectively.
In Vivo EGFR/HER2-IN-4 (compound 6d) (orally gavage; 5.1-81.4 mg/kg; for 25 days) has good cancer suppression effect in a dose-dependent manner in the constructed NCI-H1975 tumor xenograft model[1]. Animal Model: BALB/c nude mice, female, 6-7 weeks of age with NCI-H1975 tumor xenograft[1] Dosage: 81.4mg/kg, 20.4mg/kg, 5.1mg/kg Administration: Oral gavage; 81.4mg/kg and 20.4mg/kg for every other day for 25 days; 5.1mg/kg for every day for 25 days Result: Inhibited 95.21% of tumor xenografts growth at 81.4mg/kg, 71.01% at 20.4 mg/kg, and 55.1% at 5.1 mg/kg in nude mice. Animal Model: BALB/c nude mice, female, 6-7 weeks of age with NCI-H1975 tumor xenograft[1] Dosage: 10 mg/kg Administration: Oral gavage; 10 mg/kg; 25 days Result: The pharmacokinetic parameters of EGFR/HER2-IN-4 oral (10 mg/kg) Parameter Oral Tmax 4 h Cmax 92.32 μg/L AUC0-a 1030.9 μg/L*h IV 5 mg/kg half life 6.8 h oral bioavailability 46.1%
References

[1]. Debasis Das, et.al. In vivo efficacy studies of novel quinazoline derivatives as irreversible dual EGFR/HER2 inhibitors, in lung cancer xenografts (NCI-H1975) mice models. Bioorg Chem. 2020 Jun;99:103790.

Molecular Formula C24H27ClFN5O3
Molecular Weight 487.95
The content on this webpage is sourced from various professional data sources. If you have any questions or concerns regarding the content, please feel free to contact service1@chemsrc.com.